Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating ...
网页2 天之前 — Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in 12% of patients who received KEYTRUDA as a single agent, given as adjuvant treatment; the most frequent adverse ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
网页RAHWAY, N.J., September 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 ...
Keytruda keys in on survival: Promising results in high-risk early ...
网页Tue, Sep 17, 2024, 12:54 PM 3 min read. At the European Society for Medical Oncology Congress on September 13–17, promising results from the Phase III KEYNOTE-522 study involving MSD's ...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
网页2023年11月16日 — Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.
FDA approves pembrolizumab as adjuvant treatment for non …
网页On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
Keytruda Receives 40th FDA Approval - Cancer Research Institute
网页2024年6月21日 — On June 17, the FDA approved the cancer immunotherapy drug, pembrolizumab (Keytruda®), combined with chemotherapy, for the treatment of adult patients with primary advanced or recurrent endometrial cancer.
Padcev and Keytruda Double Bladder Cancer Survival - NCI
网页2023年11月30日 — UPDATE: On December 15, 2023, FDA approved enfortumab vedotin (Padcev) in combination with pembrolizumab (Keytruda) for people with bladder cancer that has spread to other parts of the body or cannot be removed surgically.
Merck wins first FDA approval for Keytruda as a treatment for ...
网页2024年9月18日 — Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated...
News Details
网页2022年12月13日 — mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a ...
FDA approves pembrolizumab combination for the first-line …
网页On October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent,...
跳至内容